Market Place
Sourcing Support
Nuvation Bio To Share Q1 2026 Financials And Business Update
20 Apr 2026 //
PR NEWSWIRE
Nuvation Bio Acquires Japan Rights to Safusidenib from Daiichi
01 Apr 2026 //
PR NEWSWIRE
Nuvation Bio Reveals 2025 Financials And Business Update
02 Mar 2026 //
PR NEWSWIRE
Nuvation Bio To Participate In Upcoming Investor Conferences
25 Feb 2026 //
PR NEWSWIRE
Nuvation Bio To Share 2025 Financials And Business Update
17 Feb 2026 //
PR NEWSWIRE
Nuvation Bio, Eisai Sign Taletrectinib Deal in Europe
12 Jan 2026 //
PHARMIWEB
Nuvation Bio Reports 2025 Results, 2026 Outlook
12 Jan 2026 //
BUSINESSWIRE
Nuvation Bio To Participate In Upcoming Investor Conferences
26 Nov 2025 //
BUSINESSWIRE
Nuvation Bio To Participate In Upcoming Investor Conferences
30 Oct 2025 //
BUSINESSWIRE
Nuvation Bio To Present Q3 2025 Financial Results And Business
20 Oct 2025 //
BUSINESSWIRE
Nuvation Bio Shares Q2 2025 Financial Results and Business Update
07 Aug 2025 //
BUSINESSWIRE
Nuvation Bio Reveals New IBTROZI Data at WCLC and ESMO Congresses
05 Aug 2025 //
BUSINESSWIRE
Onco360 Selected as National Specialty Pharmacy for Ibtrozi™
16 Jun 2025 //
GLOBENEWSWIRE
Nuvation Bio to Participate in Upcoming Investor Conferences
12 May 2025 //
BUSINESSWIRE
Nuvation Bio Reports Q1 2025 Financials and Business Update
07 May 2025 //
BUSINESSWIRE
Nuvation Bio to Present at The Citizens Life Sciences Conference
01 May 2025 //
BUSINESSWIRE
Nuvation Bio to Report Q1 2025 Results and Business Update on May
22 Apr 2025 //
BUSINESSWIRE
Nuvation Bio to Present at Jones Healthcare Innovation Conf.
02 Apr 2025 //
BUSINESSWIRE
Nuvation To Present Taletrectinib Vs. Crizotinib Data At Lung Congress
25 Mar 2025 //
BUSINESSWIRE
Nuvation Bio to Present Nonclinical Data at AACR Meeting 2025
25 Mar 2025 //
BUSINESSWIRE
Nuvation Bio Reports 2024 Financial Results and Business Update
06 Mar 2025 //
BUSINESSWIRE
Nuvation Secures Up to $250M Non-Dilutive Funding
03 Mar 2025 //
BUSINESSWIRE
Nuvation Bio To Present At TD Cowen Annual Health Care Conference
24 Feb 2025 //
BUSINESSWIRE
Nuvation Bio Launches US Expanded Access Program for Taletrectinib
03 Feb 2025 //
BUSINESSWIRE
Nuvation Gets China NMPA Nod For Taletrectinib In ROS1+ NSCLC
06 Jan 2025 //
BUSINESSWIRE
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Conference
06 Jan 2025 //
BUSINESSWIRE
FDA Accepts Nuvation’s Taletrectinib for Review in ROS1+ NSCLC
23 Dec 2024 //
BUSINESSWIRE
Nuvation Bio to Present at 7th Annual Evercore ISI HealthCONx Conf
26 Nov 2024 //
BUSINESSWIRE
Nuvation Bio Reports Q3 2024 Results & Business Update
06 Nov 2024 //
BUSINESSWIRE
Nuvation Bio to Present at the Cantor Global Healthcare Conference
09 Sep 2024 //
BUSINESSWIRE
Nuvation Bio Reports Q2 2024 Results And Business Update
05 Aug 2024 //
BUSINESSWIRE
Nuvation halts BET inhibitor program after considering phase 1 solid tumor data
05 Aug 2024 //
FIERCE BIOTECH
Nuvation Bio Updates On ROS1 Inhibitor Taletrectinib
23 Jul 2024 //
BUSINESSWIRE
Nuvation`s Taletrectinib ROS1 Inhibitor Data Published In JCO, At ASCO
01 Jun 2024 //
BUSINESSWIRE
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
29 May 2024 //
BUSINESSWIRE
Nuvation Bio shares pivotal China data for cancer drug from AnHeart buyout
23 May 2024 //
ENDPTS
Nuvation Bio Reports Q1 2024 Financial Results, Business Update
14 May 2024 //
BUSINESSWIRE
Nuvation Presents Taletrectinib ROS1 Inhibitor Data at ASCO
24 Apr 2024 //
BUSINESSWIRE
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
10 Apr 2024 //
BUSINESSWIRE
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief CO
28 Mar 2024 //
BUSINESSWIRE
Nuvation Bio nears commercial stage with AnHeart buy
26 Mar 2024 //
PHARMAPHORUM
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
25 Mar 2024 //
BUSINESSWIRE
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511
14 Mar 2024 //
BUSINESSWIRE
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
BUSINESSWIRE
Nuvation Bio Announces FDA Clearance of Investigational NDA for NUV-1511
08 Jan 2024 //
BUSINESSWIRE
Nuvation Announces Appointment of Dr. Robert Mashal to its Board of Directors
08 Jan 2024 //
BUSINESSWIRE
Nuvation Bio Announces Departure of Chief Financial Officer
13 Nov 2023 //
BUSINESSWIRE
Nuvation Bio Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
Nuvation Bio Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
BUSINESSWIRE
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board
01 Jun 2023 //
BUSINESSWIRE
Nuvation Bio Reports 1Q FYR 2023 and Provides Business Update
04 May 2023 //
BUSINESSWIRE
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
BUSINESSWIRE
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
19 Dec 2022 //
BUSINESSWIRE
Nuvation Bio Reports 3Q FYR and Provides Business Update
03 Nov 2022 //
BUSINESSWIRE
Nuvation Bio Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
Nuvation drops tumor asset and reduces staff by a third
02 Aug 2022 //
FIERCEBIOTECH
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
01 Aug 2022 //
BUSINESSWIRE
Nuvation Bio Appoints David Liu, M.D., Ph.D., as CMO and Kerry Wentworth as CRO
18 Jul 2022 //
BUSINESSWIRE
Nuvation`s new solid tumor focus hits snag on FDA hold
28 Jun 2022 //
FIERCEBIOTECH
Moneybags Nuvation deprioritizes 2 solid tumor prospects
11 May 2022 //
FIERCEBIOTECH
